An Investigator-Sponsored Phase Ib Trial of Venetoclax and SINE: Selective Inhibition of Nuclear Export in Patients with High Risk Hematologic Malignancies
This investigator-sponsored trial explores the combination of Venetoclax and Selinexor in patients with high-risk hematologic malignancies, specifically targeting Diffuse Large B-cell Lymphoma (DLBCL) and Acute Myeloid Leukemia (AML). The combination therapy aims to address unmet medical needs in refractory or relapsed cases, potentially enhancing treatment options in a competitive oncology market. Given the increasing prevalence of hematologic malignancies and the limitations of current therapies, successful outcomes could position this combination as a viable treatment alternative, influencing market dynamics and attracting interest from larger pharmaceutical entities. The collaboration with Karyopharm Therapeutics and AbbVie may also indicate strategic partnerships that could enhance commercialization efforts.
Indication: Diffuse Large B-cell Lymphoma
Modality: small molecule
Target: BCL-2 protein inhibition (by Venetoclax) and selective inhibition of nuclear export (by Selinexor)
Sponsor: Sanjay Mohan
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jun 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: BCL-2 protein inhibition (by Venetoclax) and selective inhibition of nuclear export (by Selinexor)
View original source fields
Condition raw: Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
Condition normalized: Diffuse Large B-cell Lymphoma, Acute Myeloid Leukemia, Non-Hodgkin's Lymphoma
Modality raw: small molecule
Modality normalized: small molecule
Target raw: BCL-2 protein inhibition (by Venetoclax) and selective inhibition of nuclear export (by Selinexor)
Target normalized: BCL-2 protein inhibition (by Venetoclax) and selective inhibition of nuclear export (by Selinexor)